glp 1 and liver enzymes GLP-1 Receptor Agonists in Non-Alcoholic Fatty Disease: Current Evidence Future Perspectives Repurposing GLP-1 Receptor Agonists: A

Nail-patella-elbow syndrome

We present the related studies on IR reported in recent years in Table 3, including animal models, treatment methods and results

Candidates must have high potency at both receptors, but it is unclear whether the limited experimental data available can be used to train models that accurately predict the activity at both receptors of new peptide variants

However, its mechanism of action needs to be further studied (Zhao et al., 2011)

in Spain, its current prevalence ranges between 2833%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.1315 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets